- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Weight Watchers Expands Wegovy Savings for Members
New partnership with Novo Nordisk offers up to $1,200 annual savings on FDA-approved weight loss medication.
Apr. 1, 2026 at 12:00am
Got story updates? Submit your updates here. ›
WW International, Inc. (NASDAQ: WW) has announced an expanded collaboration with Novo Nordisk to offer eligible Weight Watchers Med+ members significant savings of up to $1,200 per year on the FDA-approved weight loss medication Wegovy. This move aims to increase affordable access to GLP-1 treatment through Weight Watchers' integrated care platform.
Why it matters
The high cost of prescription weight loss medications has been a barrier for many patients seeking effective treatments. This partnership between Weight Watchers and Novo Nordisk helps address this issue by providing substantial savings to eligible members, potentially expanding access to an FDA-approved weight loss drug within Weight Watchers' holistic wellness program.
The details
Under the new agreement, eligible Weight Watchers Med+ members can now save up to $1,200 annually on the cost of Wegovy, a GLP-1 agonist approved by the FDA for chronic weight management. This expanded collaboration leverages Weight Watchers' integrated care platform to make the prescription medication more accessible to members seeking a comprehensive approach to weight loss and overall health.
- The new Wegovy savings program for Weight Watchers Med+ members launched on April 1, 2026.
The players
WW International, Inc.
A global wellness company that provides digital and in-person weight management programs, including its flagship Weight Watchers brand.
Novo Nordisk
A leading global pharmaceutical company specializing in diabetes care and other chronic conditions, including the development and manufacturing of Wegovy.
What they’re saying
“We're excited to expand our collaboration with Novo Nordisk to make Wegovy more accessible to our members. This is an important step in providing a comprehensive, integrated approach to weight management and overall health.”
— Mindy Grossman, President and CEO of WW International, Inc.
What’s next
Weight Watchers plans to promote the new Wegovy savings program to its Med+ members through its digital platforms and in-person workshops in the coming weeks.
The takeaway
This partnership between Weight Watchers and Novo Nordisk demonstrates a collaborative effort to improve access to effective weight loss treatments, combining Weight Watchers' holistic wellness approach with the benefits of an FDA-approved medication.
